about
sameAs
Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in EuropeHIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South AmericaPatterns of transmitted HIV drug resistance in Europe vary by risk groupTrends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemicHIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug UsersThe global spread of HIV-1 subtype B epidemic.Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy.Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individualsTreatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patientsTransmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics.Limited cross-border infections in patients newly diagnosed with HIV in EuropeTracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor.The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy.Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia.Identification of two distinct subsets of long-term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis.Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient.An outbreak of HIV-1 subtype G among Italian injecting drug users.Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters.Clinical and immunological aspects of HIV infection in drug addicts.Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades.Origin and evolutionary dynamics of Hepatitis B virus (HBV) genotype E in Madagascar.Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.Decreased function of Fas in patients displaying delayed progression of HIV-induced immune deficiency.Identification of a new HIV-1 BC circulating recombinant form (CRF60_BC) in Italian young men having sex with men.Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics.Local and global spatio-temporal dynamics of HIV-1 subtype F1.Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase.Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy.Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions.Identification of a possible ancestor of the subtype A1 HIV Type 1 variant circulating in the former Soviet Union.Transmission of drug-resistant HIV-1 is stabilizing in Europe.
P50
Q28474278-A32BB546-A02C-47B7-ABAB-2B8D16126917Q28481828-6A4F0E75-A8A5-4A5F-A003-6986FF0CBAC6Q28537726-E6E5788B-4338-4107-ACCB-923793C82A7DQ28540490-E0191CB4-3357-437D-AFA7-DBAE8CCA5B0CQ28552320-00E074EA-1F22-4118-BDDE-E0EB7724783AQ30388926-DABC178D-4635-475F-98A4-9B018D89A7ADQ31018156-28726CCC-2BA9-48F1-BEA7-87684E164693Q34468059-F4C704FF-4FDB-488A-9B41-AB15E56F7783Q34469240-0CAD584B-9AD4-4E40-B4F6-F8AF36FC5738Q35273824-63619F10-053C-4AF8-AD58-6FCE567FB285Q35682427-076BFD6A-DA52-4364-987B-74F371787D21Q36102566-BFDA0249-B4E8-4C58-8833-452C1E480916Q36367759-0BDDE395-5FFE-4A4C-913C-684739B529A9Q36543845-190D8CBF-EE6C-4F26-84F0-AC09B9F214BCQ36588672-C0DC6E09-AC6E-48B6-8F95-7E589CE635A3Q36766901-C83961A0-87D7-48B7-9EFC-1EBB31884C6EQ37278724-BE42411D-7F22-4863-80FF-7C99FECA4ED5Q38164573-F2E48462-CE6D-4CA8-BE20-A835A34CB81DQ38470650-7B7A65A3-101C-40AC-99B9-7F2F06362C77Q38875822-6A86E03A-A2E9-4DFD-A085-1FFB211E2235Q38890415-2777654D-FEE5-4035-A473-9AFFE58B0B9AQ38890421-6EF6D125-197D-4934-9CB3-05A6EC84DB9BQ38947377-36A32104-9DB2-44FC-A3B0-6068D159878CQ38953819-F9FD54CB-1E01-4FE5-9AE2-59AFA74EB1A6Q39275091-C5728DAE-97C9-4A3A-8469-5586988DCD20Q39473811-7F48231E-4258-47B4-BA3F-7B406ECB4BB0Q39525417-2F9FCEF1-E79C-4C5B-9E7C-18BCE7C3043AQ39562375-075F2F52-6B6C-4780-8238-D01F0F28F19DQ39880822-232CF3B1-733F-4FFC-8627-68BA334A9EF8Q40374289-B323B7E2-E9F3-4D40-9D8D-12765DA94FDCQ40396257-E3EC348E-D4E0-42D8-B002-9C44CC432307Q40741758-B94BECB3-79B6-4D29-AA4C-5DCD8398F9CDQ42225354-CDF3BA4B-B2AF-4DDB-B50A-E54490B8A2A1Q42230363-879F4927-2EB8-4A36-B24B-4B7466458ABCQ42244338-66605338-F13E-4E25-A0AB-89AD5DDF9058Q42729800-84DDCE1B-7FFE-4A15-BAC6-DBBD6584E55AQ43265349-0548F4FB-66F4-47CC-806D-6E073598F95BQ43557855-DFADDFCA-B6B7-45B3-B375-C303ACF2286BQ43926498-D3786C69-4927-4A3D-BFC6-59283407D882Q44591236-B2ABFF69-2515-4D49-9D00-A987D30DA8C8
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Claudia Balotta
@ast
Claudia Balotta
@en
Claudia Balotta
@es
Claudia Balotta
@nl
Claudia Balotta
@sl
type
label
Claudia Balotta
@ast
Claudia Balotta
@en
Claudia Balotta
@es
Claudia Balotta
@nl
Claudia Balotta
@sl
prefLabel
Claudia Balotta
@ast
Claudia Balotta
@en
Claudia Balotta
@es
Claudia Balotta
@nl
Claudia Balotta
@sl
P1053
L-7295-2017
P106
P1153
7004511267
P21
P31
P3829
P496
0000-0002-1107-9119
P569
2000-01-01T00:00:00Z